How profitable is Solana Company (Class A) (HSDT)?

In FY 2025 (10-K), HSDT converted $1.0M of revenue into a 551.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / HSDT / financials

VANI (28) FOCL (28) NRXS (36) STXS (22) ⌘ Pro Terminal →

Solana Company (Class A) (HSDT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.02 -3.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.00

Solana Company (Class A) (HSDT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $135.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSDT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HSDT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Solana Company (Class A) (NASDAQ: HSDT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.02 (-3.59% 1D, market cap $135.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HSDT ranks #761 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HSDT compare to VANI and FOCL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HSDT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, VANI (Vivani Medical Inc.) holds a E grade (28/100 RQD, P/E 3.9x, ROIC -35.0%, cap $98.3M) and FOCL (EDAP TMS S.A.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $192.1M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while HSDT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSDT?

▼

Per HSDT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001610853), Solana Company (Class A) generated $548.0K in revenue (+5.4% YoY), -$40.9M in net income, and -$16.5M in free cash flow against $303.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.00 (-0.84%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HSDT)Realized 20D OHLCV Swing Band: ±11.8%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY HSDT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 25.63 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 551.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.35-0.9% Next Q

Q2 (-2Q)

Grade E$2.33-4.3% Next Q

Q3 (-1Q)

Grade E$2.23-9.4% Next Q

Current

Grade E$2.02-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HSDT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HSDT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.41) and Max Pain ($2.12) forces dealer call-delta covering toward $6.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSDT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HSDT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HSDT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $605.0K

FY24

Rev $520.0K

FY25

Rev $548.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$548.0K	98%	-80%	-$40.9M	-$16.5M	-45%
FY 2024	$520.0K	-11.9%	-80%	-$11.7M	-$11.0M	-45%
FY 2023	$605.0K	92%	-80%	-$8.9M	-$10.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSDT)

✓Walkthrough of HSDT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HSDT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.48%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.26H $2.26L $2.02C $2.02VOL 562.1K

RES: $4.13SUP: $1.88SMA50: $2.41SMA200: $2.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSDT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HSDT Butterfly Map → + Track HSDT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +5.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HSDT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HSDT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HSDT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSDT)

Health Care Rank #761 of 1015 ⚔️ VANI vs HSDT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HSDT vs. VANI, FOCL, NRXS, STXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Solana Company (Class A) (HSDT) ranks #761 by composite RQD confidence (31/100, grade E) and #616 by equity capitalization ($135.5M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while HSDT leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. NRXS currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with HSDT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HSDT ACTIVE Solana Company (Class A)	E	31/100	—	96.0%	-35.0%	-3.59%	$135.5M	Benchmark Subject
VANI Vivani Medical Inc.	E	28/100	3.9x	—	-35.0%	0.00%	$98.3M	/vani-vs-hsdt →
FOCL EDAP TMS S.A.	E	28/100	—	42.5%	-35.0%	+3.83%	$192.1M	/focl-vs-hsdt →
NRXS Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-7.43%	$89.5M	/nrxs-vs-hsdt →
STXS Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	+2.03%	$86.4M	/stxs-vs-hsdt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001610853 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Solana Company (Class A) (HSDT) reported GAAP revenue of $548.0K (+5.4% vs. FY2024 revenue of $520.0K , and -9.4% cumulative change since FY2023) , GAAP net income of -$40.9M, operating cash flow of -$16.5M, and free cash flow of -$16.5M (-49.5% YoY). On the balance sheet, HSDT closed FY2025 with $303.9M in total assets against $0 in total debt (Altman Z-Score: 25.63, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$548.0K	-$40.9M	-$16.5M	-$16.5M	$303.9M	—
FY2024 (FY)	2024-12-31	$520.0K	-$11.7M	-$11.0M	-$11.0M	$3.5M	—
FY2023 (FY)	2023-12-31	$605.0K	-$8.9M	-$10.4M	-$10.4M	—	—

3. HSDT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSDT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HSDT compare to VANI and FOCL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HSDT?

Where is HSDT trading relative to its 50-day, 200-day, and 52-week technical levels?

HSDT last traded at $2.02 (-3.59% on volume of 336,849 shares), positioning the stock -16.18% below its 50-day simple moving average ($2.41) and -3.35% below its 200-day simple moving average ($2.09). Across its 52-week range of $1.18 to $5.99, HSDT sits at the 17.5% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($1.78 to $2.26).

Direct Sub-Reports: HSDT RQD Cockpit HSDT 12M Forecast HSDT Earnings & Move HSDT Dividends & DRIP HSDT Insiders & 13F HSDT Whale Options HSDT Profit Sankey HSDT News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

HSDT — Solana Company (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Solana Company (Class A) (HSDT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.02 (-3.59% 1D, market capitalization $135.5M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of -11.27%.
Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 25.63, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Solana Company (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The profile describes the issuer's market capitalization as $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Solana Company (Class A) (HSDT) reported $548.0K in annual revenue (up from $520.0K in FY2024, +5.4% YoY) and -$40.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($605.0K revenue, -$8.9M net income) through FY2025, HSDT scaled operating cash flow to -$16.5M and free cash flow to -$16.5M, backed by $303.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.27% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.18 – $5.99 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations, and no 2nd-order bottlenecks can be traced from it.

Key Question #1: Can HSDT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $548.0K and free cash flow of -$16.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is HSDT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HSDT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Solana Company (Class A) (HSDT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HSDT Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 23h ago

Solana Company Estimates – NASDAQ:HSDT

TradingView report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST bloomingbit • 1d ago

US Crypto-Linked Stocks Rise in Premarket Trading; Solana Company Surges 14%

bloomingbit report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Hong Kong's 2026 group includes the only company helping run a blockchain network: Solana Company.

Stock Titan report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

China vs. Crypto Isn’t Over Yet: Solana Company CEO Says Beijing Is Studying the Technology ‘Very Closely

Benzinga report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Solana Company Establishes Asia-Pacific Headquarters in Hong Kong

www.marketscreener.com report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Solana Company designated strategic enterprise by Hong Kong

Investing.com Canada report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

SkyAI: The $3 Tender Offer Doesn't Solve The Valuation Problem (NASDAQ:SKYA)

Seeking Alpha report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Hong Kong names Nasdaq-listed Solana Company a strategic enterprise

TradingView report covering Solana Company (Class A) (HSDT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSDT Bull vs. Bear Conversation Board — What's Your Call at $2.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSDT 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.65 (+26.8%)

📌 Pinned Debate

Balance-sheet forensics score is anchored by an Altman Z-Score of 25.63 and a Debt/Equity ratio of 0.5, with cash rising to $7.3M in FY

Balance-sheet forensics score is anchored by an Altman Z-Score of 25.63 and a Debt/Equity ratio of 0.5, with cash rising to $7.3M in FY 2025.. When you look under the hood at HSDT, Fundamental Cash Engine is 9/20 with 96.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $5.99. My 12M target is $2.65.

EarningsSniper 🐂 BULL

@FadeTheHype Shorting a 4/20 institutional whale-flow stock at $2.09 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.57 (-24.9%)

Spot @ $2.09

Operating loss widened to -$243.8M in FY 2025 with ROIC at -35% and FCF yield at -11.27%, while insider conviction scores only 3 / 20.

Here is the bear case nobody on the bull side wants to address on HSDT: Operating loss widened to -$243.8M in FY 2025 with ROIC at -35% and FCF yield at -11.27%, while insider conviction scores only 3 / 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.